Bookmark and Share
BioAssay: AID 743457

QFRET-based biochemical high throughput dose response assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2)

Name: QFRET-based biochemical high throughput dose response assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2). ..more
_
   
 Tested Compounds
 Tested Compounds
All(240)
 
 
Active(1)
 
 
Inactive(239)
 
 
 Tested Substances
 Tested Substances
All(240)
 
 
Active(1)
 
 
Inactive(239)
 
 
 Related BioAssays
 Related BioAssays
AID: 743457
Data Source: The Scripps Research Institute Molecular Screening Center (HGIII-SPLA2_INH_QFRET_1536_3XIC50 DRUN)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2014-04-11

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compound: 1
Related Experiments
AIDNameTypeComment
743126QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2)Screeningdepositor-specified cross reference: Primary Assay (HGIII-SPLA2 INH in singlicate)
743138Summary of the probe development effort to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2).Summarydepositor-specified cross reference: Summary
743280QFRET-based biochemical high throughput confirmation assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2)Screeningsame project related to Summary assay
743282Counterscreen for inhibitors of the HGIII-SPLA2: QFRET-based biochemical high throughput screening assay to identify inhibitors that optically interfere with 535nm fluorescenceScreeningsame project related to Summary assay
743455Counterscreen for inhibitors of the HGIII-SPLA2: QFRET-based biochemical high throughput dose response assay to identify inhibitors that optically interfere with 535nm fluorescenceConfirmatorysame project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Michael H. Gelb, University of Washington
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number R37HL036235
Grant Proposal PI: Michael H. Gelb, University of Washington
External Assay ID: HGIII-SPLA2_INH_QFRET_1536_3XIC50 DRUN

Name: QFRET-based biochemical high throughput dose response assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2).

Description:

Phospholipases A2 (PLA2s) are a class of enzymes that hydrolyze the sn-2 ester of glycerophospholipids to release a free fatty acid and a lysophospholipid [1]. Secreted PLA2s (sPLA2s) have been implicated in the pathogenesis of inflammatory disease in humans. Inhibitors of many of the sPLA2s in the human and mouse genome have been made, but to date no inhibitor of human group III sPLA2 (hGIII-sPLA2) has been discovered. The amino acid sequence of hGIII-sPLA2 is similar to that of the sPLA2 in honey bee venom. This enzyme was discovered about 10 years ago, cloned, its enzymatic properties studied, and a knockout mouse constructed [2]. Over the past few years it has been shown that this enzyme is highly expressed in mast cells [3]. The enzyme is secreted from human and mouse mast cells and, together with lipocalin-type prostaglandin D2 synthase, leads to PGD2 production. Presumably the sPLA2 liberates arachidonic acid from the sn-2 position of membrane phospholipids to provide the arachidonic acid for PGD2 production. PGD2 then binds to its receptor (DP1) on the surface of mast cells leading to mast cell maturation. Mice lacking mGIII-sPLA2 produce immature mast cells [4]. These mice show a dramatic reduction in anaphylatic responses, a process that is well known to be mediated in part by mast cells. The results provide a strong rational for the development of GIII-sPLA2 inhibitors to treat mast cell-mediate diseases.

References:

1. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem. 2008;77:495-520.
2. Valentin E, Ghomashchi F, Gelb MH, Lazdunski M, Lambeau G. Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme. J Biol Chem. 2000 Mar 17;275(11):7492-7496.
3. Triggiani M, Giannattasio G, Calabrese C, Loffredo S, Granata F, Fiorello A, Santini M, Gelb MH, Marone G. Lung mast cells are a source of secreted phospholipases A2. J Allergy Clin Immunol. 2009 Sep;124(3):558-565.
4. Taketomi Y, Ueno N, Kojima T, Sato H, Murase R, Yamamoto K, Tanaka S, Sakanaka M, Nakamura M, Nishito Y, Kawana M, Kambe N, Ikeda K, Taguchi R, Nakamizo S, Kabashima K, Gelb MH, Arita M, Yokomizo T, Nakamura M, Watanabe K, Hirai H, Nakamura M, Okayama Y, Ra C, Aritake K, Urade Y, Morimoto K, Sugimoto Y, Shimizu T, Narumiya S, Hara S, Murakami M. Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nat Immunol. 2013 Jun;14(6):554-563.

Keywords:

DRUN, dose response, dose, dilution, confirm, confirmation, triplicate, human group III secreted phospholipase A2, HGIII-sPLA2, PLA2, Phospholipase A2, HGIII-SPLA2, BODIPY substrate, QFRET, BODIPY PC-A2, FRET, BODIPY FL pentanoic acid, biochemical, fluorescence, inhibition, modulators, HTS, high throughput screen, 1536, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC inhibitor, fluorescence, HTS, Molecular Libraries Probe Production Centers Network, MLPCN
Protocol
Assay Overview:

The purpose of this assay is to determine dose responses curves for compounds identified as active in a previous set of experiments entitled, "QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2)" (PubChem AID 743126) and "QFRET-based biochemical high throughput confirmation assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2) (PubChem AID 743280) and were inactive in a set of experiments entitled, "Counterscreen for inhibitors of the HGIII-SPLA2: QFRET-based biochemical high throughput screening assay to identify inhibitors that optically interfere with 535nm fluorescence (PubChem AID 743282). In this assay, HGIII-sPLA2 enzyme is pre-incubated with test compounds, followed by incubation with the BODIPY PC-A2 substrate in a suspension of DOPC:DOPG liposomes. Fluorescence is determined at at specific time point. The cleavage of the BODIPY FL pentanoic acid substituent at the sn-2 position is a PLA2-dependent increase in BODIPY FL fluorescence emission detected in the range 515-545nm. As designed, test compounds that act as HGIII-sPLA2 inhibitors will prevent the cleavage of the BODIPY FL pentanoic acid at the sn-2 position, resulting in a decrease in well fluorescence. Compounds are tested in triplicate using a 10-point 1:3 dilution series starting at a maximum nomimal test concentration of 122 uM.
Protocol Summary:

Prior to the start of the assay, 2 microliters of assay buffer (50mM Tris-HCl pH 8.9, 100mM NaCl and 1mM CaCl2) were dispensed into columns 1 thru column 3 of 1536 microtiter plates. Next, 2 microliters of assay buffer containing 2.63ug/mL of HGIII-sPLA2 enzyme were dispensed into columns 4 thru 48. Then, 37 nL of test compound in DMSO or DMSO alone (1.2% final concentration) were added to the appropriate wells and incubated for 15 minutes at 25 degrees Celsius. The assay start by the addition of 1 microliter of 9 uM BODIPY PC-A2 substrate incorporated in liposomes containing 45 uM DOPC and 45 uM DOPG in assay buffer to all wells. Plates were centrifuged and after 35 minutes of incubation at 25 degrees Celsius, fluorescence was measured at 485nm excitation and 535nm emission.

The percent inhibition for each compound was calculated as follows:

%Inhibition= 100*( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )

Where:

Test_Compound is defined as wells containing HGIII-SPLA2 enzyme in the presence test compound and BODIPY PC-A2 substrate.
Low_Control is defined as wells containing HGIII-SPLA2, DMSO and BODIPY PC-A2 substrate.
High_Control is defined as wells containing DMSO, BODIPY PC-A2 but, no HGIII-SPLA2 enzyme.

For each test compound, percent inhibition was plotted against compound concentration. A four parameter equation describing a sigmoidal dose-response curve was then fitted with adjustable baseline using Assay Explorer software (Symyx Technologies Inc). The reported IC50 values were generated from fitted curves by solving for the X-intercept value at the 50% inhibition level of the Y-intercept value. In cases where the highest concentration tested (i.e. 122 uM) did not result in greater than 50% inhibition, the IC50 was determined manually as greater than 122 uM.

PubChem Activity Outcome and Score:

Compounds with an IC50 greater than 10 uM were considered inactive. Compounds with an IC50 equal to or less than 10 uM were considered active.

The PubChem Activity Score range for active compounds is 100-100, and for inactive compounds 0-0.

List of Reagents:

HGIII-sPLA2 enzyme (supplied by Assay Provider)
Red/Green BODIPY PC-A2 (Life Technologies, part A10072)
Dioleoylphosphatidylcholine (DOPC) (Avanti Polar Lipids, part 850375)
Dioleoylphosphatidylglycerol (DOPG) (Avanti Polar Lipids, part 840475)
Tris (Amresco, part 0497)
NaCl (Fisher, part S640)
CaCl2.2H20 (calcium chloride dihydrate) (Fisher, part C79)
1536-well plates (Corning, part 7261)
Comment
Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that non-specifically modulate luciferase activity, and compounds that quench or emit luminescence within the well. All test compound concentrations reported are nominal; the specific concentration for a particular test compound may vary based upon the actual sample provided by the MLSMR. The MLSMR was not able to provide all compounds selected for testing in this assay.
Categorized Comment
Assay: Dictionary: Version: 0.1

Assay: CurveFit [1]: Equation: =( ( [Maximal Response] * [Concentration]^[Hill Slope] ) / ( [Inflection Point Concentration]^[Hill Slope] + [Concentration]^[Hill Slope] ) ) + [Baseline Response]

Assay: CurveFit [1]: Mask: Excluded Points

Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Qualifierinhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.String
2IC50*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) shown in micromolar.FloatμM
3LogIC50Log10 of the qualified IC50 (IC50) from the inhibitor assay in M concentrationFloat
4Maximal ResponseThe maximal or asymptotic response above the baseline as concentration increases without bound.Float
5Baseline ResponseAdjustable baseline of the curve fit, minimal response value.Float
6Inflection Point ConcentrationThe concentration value for the inflection point of the curve.FloatμM
7Chi SquareA measure for the 'goodness' of a fit. The chi-square test (Snedecor and Cochran, 1989) is used to test if a sample of data came from a population with a specific distribution.Float
8RsquareThis statistic measures how successful the fit explains the variation of the data; R-square is the square of the correlation between the response values and the predicted response values.Float
9Number of DataPointsOverall number of data points of normalized percent inhibition that was used for calculations (includes all concentration points); in some cases a data point can be excluded as outlier.Integer
10Hill SlopeThe variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.Float
11Response RangeThe range of Y.Float
12Excluded PointsFlags to indicate which of the dose-response points were excluded from analysis. (1) means the point was excluded and (0) means the point was not excluded.String
13Inhibition at 0.0062 uM [1] (0.0062μM**)Value of % inhibition at 0.0062 uM compound concentration; replicate [1]Float%
14Inhibition at 0.0062 uM [2] (0.0062μM**)Value of % inhibition at 0.0062 uM compound concentration; replicate [2]Float%
15Inhibition at 0.0062 uM [3] (0.0062μM**)Value of % inhibition at 0.0062 uM compound concentration; replicate [3]Float%
16Inhibition at 0.019 uM [1] (0.019μM**)Value of % inhibition at 0.019 uM compound concentration; replicate [1]Float%
17Inhibition at 0.019 uM [2] (0.019μM**)Value of % inhibition at 0.019 uM compound concentration; replicate [2]Float%
18Inhibition at 0.019 uM [3] (0.019μM**)Value of % inhibition at 0.019 uM compound concentration; replicate [3]Float%
19Inhibition at 0.056 uM [1] (0.056μM**)Value of % inhibition at 0.056 uM compound concentration; replicate [1]Float%
20Inhibition at 0.056 uM [2] (0.056μM**)Value of % inhibition at 0.056 uM compound concentration; replicate [2]Float%
21Inhibition at 0.056 uM [3] (0.056μM**)Value of % inhibition at 0.056 uM compound concentration; replicate [3]Float%
22Inhibition at 0.17 uM [1] (0.17μM**)Value of % inhibition at 0.17 uM compound concentration; replicate [1]Float%
23Inhibition at 0.17 uM [2] (0.17μM**)Value of % inhibition at 0.17 uM compound concentration; replicate [2]Float%
24Inhibition at 0.17 uM [3] (0.17μM**)Value of % inhibition at 0.17 uM compound concentration; replicate [3]Float%
25Inhibition at 0.5 uM [1] (0.5μM**)Value of % inhibition at 0.5 uM compound concentration; replicate [1]Float%
26Inhibition at 0.5 uM [2] (0.5μM**)Value of % inhibition at 0.5 uM compound concentration; replicate [2]Float%
27Inhibition at 0.5 uM [3] (0.5μM**)Value of % inhibition at 0.5 uM compound concentration; replicate [3]Float%
28Inhibition at 1.5 uM [1] (1.5μM**)Value of % inhibition at 1.5 uM compound concentration; replicate [1]Float%
29Inhibition at 1.5 uM [2] (1.5μM**)Value of % inhibition at 1.5 uM compound concentration; replicate [2]Float%
30Inhibition at 1.5 uM [3] (1.5μM**)Value of % inhibition at 1.5 uM compound concentration; replicate [3]Float%
31Inhibition at 4.5 uM [1] (4.5μM**)Value of % inhibition at 4.5 uM compound concentration; replicate [1]Float%
32Inhibition at 4.5 uM [2] (4.5μM**)Value of % inhibition at 4.5 uM compound concentration; replicate [2]Float%
33Inhibition at 4.5 uM [3] (4.5μM**)Value of % inhibition at 4.5 uM compound concentration; replicate [3]Float%
34Inhibition at 13.6 uM [1] (13.6μM**)Value of % inhibition at 13.6 uM compound concentration; replicate [1]Float%
35Inhibition at 13.6 uM [2] (13.6μM**)Value of % inhibition at 13.6 uM compound concentration; replicate [2]Float%
36Inhibition at 13.6 uM [3] (13.6μM**)Value of % inhibition at 13.6 uM compound concentration; replicate [3]Float%
37Inhibition at 40.7 uM [1] (40.7μM**)Value of % inhibition at 40.7 uM compound concentration; replicate [1]Float%
38Inhibition at 40.7 uM [2] (40.7μM**)Value of % inhibition at 40.7 uM compound concentration; replicate [2]Float%
39Inhibition at 40.7 uM [3] (40.7μM**)Value of % inhibition at 40.7 uM compound concentration; replicate [3]Float%
40Inhibition at 122 uM [1] (122μM**)Value of % inhibition at 122 uM compound concentration; replicate [1]Float%
41Inhibition at 122 uM [2] (122μM**)Value of % inhibition at 122 uM compound concentration; replicate [1]Float%
42Inhibition at 122 uM [3] (122μM**)Value of % inhibition at 122 uM compound concentration; replicate [3]Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: R37HL036235

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: